Abiopharma

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

📋 Halladay Benjamin (Officer) plans to sell 7K shares of Esperion Therapeutics, Inc. (at $3.67 each, total $27K) Filed: Dec 17, 2025 | ID: 007812

📋 Linetsky David (Member of immediate family of any of the foregoing) plans to sell 94 shares of Phreesia, Inc. (at $16.49 each, total $2K) Filed: Dec 17, 2025 | ID: 007811

Incyte anuncia que la Comisión Europea aprueba Minjuvi® (tafasitamab) para el tratamiento del linfoma folicular en recaída o refractario

Administrative update #SUPPL-1 for GLAXOSMITHKLINE LLC. Status: Approval. Decision date: 12/16/2025

📋 Davis John E (Officer) plans to sell 5K shares of ARTIVION, INC. (at $45.11 each, total $226K) Filed: Dec 16, 2025 | ID: 003564

Final approval of NDA #NDA #210858 for SILDENAFIL. Decision date: 12/16/2025

Director BOURLA ALBERT 🟢 acquired 23 shares (1 derivative) of PFIZER INC (PFE) Transaction Date: Dec 15, 2025 | Filing ID: 010078

How to Make Your Airpods Louder

Latest About Microsoft Surface Laptop 7

Latest About 27″ Acer Predator X27 Monitor

The Best Laptops for Photo Editing (2026)

What to Do If Your Verizon Is Experiencing an Outage

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails